Pfizer

News
FDA approves second Neupogen biosimilar

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.